Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinib

24 Feb 2024

Abstract excerpt

Apatinib was the first anti-angiogenic agent approved for treatment of metastatic gastric cancer (GC). However, the emergence of resistance was inevitable. Thus investigating new and valuable off-target effect of apatinib directly against cancer cells is of great significance. Here, we identified extra spindle pole bodies-like 1 (ESPL1) was responsible for apatinib resistance in GC cells through CRISPR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Mechanisms and Therapy
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38402402
DOI: 10.1186/s12935-024-03233-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinibPMID 38402402Read ↗

Pan-Cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancerSemantic proximity Read ↗

PRMT1-catalyzed NUSAP1 methylation enhances Notch2 signaling and 5-FU resistance in gastric cancerSemantic proximity Read ↗

AKAP8L enhances the stemness and chemoresistance of gastric cancer cells by stabilizing SCD1 mRNASemantic proximity Read ↗

Identifying therapeutic targets in gastric cancer: the current status and future direction.Semantic proximity Read ↗

PRMT1-Catalyzed NUSAP1 Methylation Enhances Notch2 Signaling and 5-FU Resistance in Gastric CancerSemantic proximity Read ↗

The CAGE–MiR-181b-5p–S1PR1 Axis Regulates Anticancer Drug Resistance and Autophagy in Gastric Cancer CellsSemantic proximity Read ↗

Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to DasatinibSemantic proximity Read ↗

LINC-PINT suppresses cisplatin resistance in gastric cancer by inhibiting autophagy activation via epigenetic silencing of ATG5 by EZH2Semantic proximity Read ↗

RP11-616M22.7 recapitulates imatinib resistance in gastrointestinal stromal tumorSemantic proximity Read ↗

Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature ReviewSemantic proximity Read ↗

ESPL1 is Elevated in Hepatocellular Carcinoma and Predicts PrognosisSemantic proximity Read ↗

Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.